Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Can-Fite BioPharma Ltd. (NYSE American: CANF) announces that Dr. Sari Fishman will present at the BIO Digital Convention on June 10-11 & 14-18, 2021. Can-Fite has secured approximately $20 million from out-licensing agreements for its drug candidates, with potential milestone payments of up to $130 million. The company anticipates key developments, including topline data from Phase III psoriasis and Phase II COVID-19 trials, as well as initiating pivotal trials in liver cancer and NASH by year-end.

Can-Fite BioPharma Ltd (NYSE American: CANF) reported its financial results for Q1 2021, revealing revenues of $0.15 million, down 25.2% from $0.20 million in Q1 2020. The company secured a $42.7 million out-licensing deal with Ewopharma, including $2.25 million upfront and up to $40.45 million contingent on milestones. The Phase III Comfort™ psoriasis study reached 75% enrollment, with topline results anticipated in Q4 2021. Can-Fite’s R&D expenses declined by 65.5% to $1.30 million, while general and administrative expenses rose to $1.01 million. Future trials for liver cancer and NASH are set for late 2021.

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will appear on The RedChip Money Report on May 29th, at 7 p.m. local time, reaching 73 million homes in the U.S. The interview will cover upcoming milestones and updates on Can-Fite's drug pipeline, including Piclidenoson and Namodenoson, which target conditions like psoriasis and liver cancer. Piclidenoson is in Phase III trials for psoriasis and Phase II studies for COVID-19, while Namodenoson has shown promise in treating liver cancer and has received Orphan Drug Designation.

Can-Fite BioPharma Ltd (NYSE American: CANF) will present at Benzinga’s Global SmallCap Conference on May 13, 2021. CEO Dr. Pnina Fishman will discuss the company’s advancements in treating psoriasis, liver cancer, and NASH. Can-Fite's drug candidates are in Phase II and Phase III trials, showcasing clinical proof of concept. The company’s lead drug, Piclidenoson, targets moderate COVID-19, while Namodenoson is set for Phase III for hepatocellular carcinoma and has received Orphan Drug and Fast Track Designation from the FDA.

Can-Fite BioPharma Ltd (NYSE American: CANF) reported that 75% of patients have been enrolled in its Phase III Comfort™ study for Piclidenoson, targeting moderate to severe plaque psoriasis. The study aims to establish the drug's superiority over placebo and non-inferiority to Apremilast, with enrollment expected to finalize in Q3 2021 and topline results anticipated in Q4 2021. The company has received over $20 million from distribution agreements for Piclidenoson, which is out-licensed in several countries. The psoriasis therapeutic market is projected to hit $11.3 billion by 2025.

Can-Fite BioPharma Ltd (NYSE American: CANF) expands its Phase II COVID-19 study of Piclidenoson to Romania and Bulgaria. The randomized, double-blind study evaluates Piclidenoson with standard care versus placebo in hospitalized patients. The treatment duration is up to 28 days, with assessments at Day 29 focusing on respiratory status and safety. Piclidenoson shows promise due to its anti-inflammatory effects and potential to combat COVID-19's severity. The CEO emphasizes the drug's safety and efficacy as recruitment accelerates in Europe.

Can-Fite BioPharma (NYSE American: CANF) announced the initiation of preclinical studies for its drug candidates Piclidenoson and Namodenoson, in preparation for future NDA and MAA submissions to the FDA and EMA. Piclidenoson is currently in the COMFORT Phase III study for psoriasis, while Namodenoson, which has Orphan Drug and Fast Track Status, will begin a Phase III study for hepatocellular cancer by Q4 2021. The company aims to obtain marketing approvals for both drugs, addressing significant market needs.

Can-Fite BioPharma Ltd (NYSE American: CANF) announced successful pre-clinical studies showing that a CBD-rich T3/C15 cannabis fraction inhibits liver cancer cell growth. This mechanism targets the A3 adenosine receptor (A3AR), crucial in liver cancer treatment. The company’s drug candidate Namodenoson is set to enter a Phase III study for advanced liver cancer in Q4 2021. The global medical cannabis market is projected to grow to $56.7 billion by 2026, highlighting significant market opportunities for Can-Fite’s cannabinoid-based therapies.

Can-Fite BioPharma Ltd. (NYSE American: CANF) has announced that its six distribution agreements for drug candidates Piclidenoson and Namodenoson could yield up to $130 million in milestone payments, alongside double-digit royalties on net sales. The company has already secured over $20 million in non-dilutive upfront and milestone payments. Territories covered include Canada, Spain, Switzerland, and more, with further discussions targeting larger markets like the U.S. and Japan. CEO Dr. Pnina Fishman emphasized the strategic growth potential in untapped markets.